Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  BioPharma  /  Bioalliance Pharma richting € 8 in 2014 ? Heden; € 4,25.

Ontvang nu dagelijks onze kooptips!

word abonnee

BioPharma« Terug naar discussie overzicht

Bioalliance Pharma richting € 8 in 2014 ? Heden; € 4,25.

442 Posts
Pagina: «« 1 ... 18 19 20 21 22 23 »» | Laatste | Omlaag ↓
  1. [verwijderd] 20 november 2014 09:50
    quote:

    bakker1628 schreef op 20 november 2014 08:08:

    [...]

    Ik ben hier geen voorstander van, aangezien je dan de vorige berichten niet meer ( makkelijk ) kan zien. Ik dan ook gevraagd aan IEX om deze tread in zin geheel te verplaatsen naar BioPharma.
    Tread is inmiddels verplaats

    HOME/FORUM/BIOPHARMA/BIOALLIANCE PHARMA RICHTING € 8 IN 2014 ? HEDEN; € 4,25.
  2. [verwijderd] 20 november 2014 09:55
    quote:

    bakker1628 schreef op 19 november 2014 08:38:

    [...]

    Ter info, ik zit zelf bij Todays, daar is ook nog geen bericht ( terwijl ik dit normaal wel altid krijg ), dus nog even geduld. Als ik een bericht krijg zal ik dat wel even laten weten, dan kan je het ook bij Binck checken.
    Zoals beloofd :

    2014/11/19 12:10:27 Today's Brokers Corporate Action News Please take note of the following information relating to a security held in your account.

    Corporate Action News for ONXEO

    Please be advised that ONXEO has announced a subscription rights offering through which the Company will issue shareholders transferrable rights to subscribe to its common stock.

    This information is provided for general purposes only and once Today's Brokers has obtained definitive information regarding this event, including terms and applicable deadlines, a follow up notification will be supplied to eligible holders. In the interim, we recommend that you contact the Investor Relations Department (see company website) or refer to any publicly available financial information websites (e.g. EDGAR, Yahoo Finance).

    Today's Klantenservice
  8. [verwijderd] 24 november 2014 19:23
    Onxeo announces positive DSMB recommendation for its phase III trial with Livatag

    Nov 24 (Reuters) - Onxeo SA :

    * Onxeo announces positive DSMB recommendation for its phase III trial with Livatag in primary liver cancer Source text for Eikon: Further company coverage: (Gdynia Newsroom: +48 58 698 39 20)

    www.reuters.com/article/2014/11/24/on...
  15. [verwijderd] 3 december 2014 22:28
    quote:

    beurspiet schreef op 3 december 2014 14:39:

    enkel "institutionelen" binnen Fr kunnen deelnemen , wij particulieren krijgen gewoon uitbetaling recht !
    Volgens mij niet, ik heb via mijn broker de vraag gekregen of ik gebruik wilde maken van mijn rights. Wat ik dan ook gedaan heb, tot op heden staan ze nog in mijn portefeuille onder de code *BIO1.RTS2

    Zodra ze zijn bijgeboekt laat ik het wel weten.
  17. [verwijderd] 9 januari 2015 07:00
    Onxeo to Present at Biotech Showcase™ Annual Conference during JP Morgan Healthcare Conference

    Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO) (Euronext Paris, NASDAQ OMX Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced that Judith Greciet, CEO of Onxeo, will be giving a corporate overview of Onxeo on Wednesday, January 14, 2015 at the Biotech Showcase 2015 Conference which is being held in San Francisco, CA (USA).

    With more than 1,500 investors and companies participating, the Biotech Showcase is one of the largest annual international healthcare investor conferences and runs parallel to the JP Morgan Healthcare Conference (San Francisco, January 12-15, 2015).

    The details of Onxeo’s presentation are as follows:

    Event:


    Biotech Showcase 2015 Conference

    Date:

    Wednesday, January 14, 2015

    Time:

    3:30 p.m. (PST)

    Location:

    Room Hearst (4th floor) - Parc 55 Wyndham San Francisco Union Square Hotel,
    San Francisco

    About Biotech Showcase™
    Co-produced by Demy-Colton Life Science Advisors and EBD Group, Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies an opportunity to present to, and meet with, investors and pharmaceutical executives during the course of one of the industry’s largest annual healthcare investor conferences. Now in its seventh year, Biotech Showcase is expected to attract upwards of 1,500 attendees.

    About Onxeo
    Onxeo has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives to “make the difference”. The Onxeo teams are determined to develop innovative medicines to provide patients with hope and significantly improve their lives.

    Key products at advanced development stage are:
    Livatag® (Doxorubicin Transdrug™): Phase III in hepatocellular carcinoma
    Validive® (Clonidine Lauriad®): Phase II in severe oral mucositis: Positive preliminary top-line results
    Beleodaq® (belinostat): registered in the US in peripheral T-cell lymphoma
    For more information, visit the website www.onxeo.com

    Disclaimer

    This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2013 Reference Document filed with the AMF on April 7, 2014, which is available on the AMF website (http://www.amf-france.org) or on the company’s website (www.onxeo.com).

    Onxeo
    Judith Greciet, CEO
    j.greciet@onxeo.com
    or
    Nicolas Fellmann, CFO
    n.fellmann@onxeo.com
    +33 1 45 58 76 00
  18. [verwijderd] 28 januari 2015 08:27
    Onxeo’s shares transferred to Compartment B on Euronext Paris
    Euronext Paris

    26 JAN, 2015
    Onxeo S.A. (Euronext Paris, NASDAQ OMX Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announces that its shares will be transferred from Compartment C to Compartment B of the NYSE Euronext Paris with effect from January 28, 2015.

    According to the regulations of NYSE Euronext, compartment changes are made annually on the basis of the market capitalization of the last 60 trading days of the year. Compartment B consists of listed companies with a market capitalization of between €150 million and €1 billion.

    The transfer comes a few weeks after the selection of Onxeo to enter the EnterNext© PEA-PME 150, a benchmark index launched in November 2014 in response to the industry’s demand for new benchmarks.

    “The transfer of our shares to Compartment B is a key event showing the progression of our market value. After a successful merger in 2014, Onxeo now relies on strong fundamentals: 3 products in an advanced clinical stage, all positioned on dynamic markets in the orphan oncology field, and on an experienced team who already registered 3 products in the US and Europe, today commercialized by our partners. The company has also strengthened its own funds with a significant capital increase in December 2014. These assets and our reinforced market visibility should increase our attractivity to international investors in the next months”, comments Nicolas Fellmann, CFO of Onxeo.
  20. [verwijderd] 28 januari 2015 21:09
    Shareholders Letter January 2015

    Dear Shareholders,

    2014 marked a turning point in the history of our group.
    The merger, completed a little more than six months ago, was a key step to position Onxeo as a strong player in orphan oncology.
    Today, Onxeo conceives and develops innovative treatments for rare cancer patients, highly promising in terms of therapeutic value and market potential.

    2015 will bring exciting news on our major programs at an advanced clinical stage, Livatag®, Validive® and Beleodaq®.

    This letter will tell you more about it.

    Our ambition for the future is to strengthen the growth momentum initiated these past months through the development of our programs and our partnering activities. This growth should be enhanced by the orphan oncology market dynamism, one of the fastest growing market in health industry.
    We would like to thank you for your continued trust and, through this letter, reaffirm the commitment of our international and experienced teams to build Onxeo’s future success and bring innovative therapeutics for rare cancers to patients. We sincerely hope that you will keep supporting us in this exciting adventure.

    With my very best regards.
    Judith Greciet - CEO of Onxeo

    FEBRUARY 2014
    Validive® granted with Fast Track status
    by US regulatory agency (FDA) allowing
    accelerated review procedure

    APRIL 2014
    4th DSMB positive recommendation re.
    Livatag® safety profile in ReLive phase III
    trial

    MAY 2014
    Livatag® granted fast track designation
    by FDA

    JUNE 2014
    Merger between BioAlliance Pharma
    and Topotarget to create Onxeo

    JULY 2014
    Beleodaq® US market approval (PTCL)
    & commercialization started in the US

    OCTOBER 2014
    Positive preliminary top-line results
    Phase II for Validive® (severe oral
    mucositis)

    NOVEMBER 2014
    5th DSMB positive recommendation re.
    Livatag® safety profile

    DECEMBER 2014
    Successful rights issue completed for a
    total of €40.7m

    Onxeo key programs: From 2014 to 2015 perspectives

    Beleodaq®: HDAC inhibitor already approved and launched in the US in August for rare blood cancer PTCL* in 2nd line.
    • Preparation of indication extension in PTCL 1st line jointly with Spectrum pharmaceuticals => trial initiation early 2016.

    Validive®: Mucoadhesive tablet to prevent severe oral inflammation induced by radiation therapy in H&N cancer treatment.
    • Phase II final report under preparation (positive results announced October 2014) => phase III initiation end 2015.
    • Evaluation of partnering opportunities.
    * T-Cell Peripheral Lymphoma

    Livatag®: chemotherapy acting like a Trojan horse for the treatment of liver cancer, bypassing tumor cell resistance thanks to innovative nanoparticle technology.
    • Positive data safety reviews by international board of experts (DSMB) twice yearly since study initiation => next DSMB Q2 2015.
    • Phase III study enrolment ongoing in 8 European countries and the US. 35 active centers => 10 to 15 additional centers planned to be opened
442 Posts
Pagina: «« 1 ... 18 19 20 21 22 23 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 913,25 -0,03%
EUR/USD 1,0870 +0,03%
FTSE 100 8.420,26 -0,22%
Germany40^ 18.716,50 +0,06%
Gold spot 2.415,21 0,00%
NY-Nasdaq Composite 16.685,97 -0,07%

Stijgers

NX FIL...
+8,76%
VIVORY...
+6,12%
Sif Ho...
+4,09%
RENEWI
+3,21%
HEIJMA...
+3,08%

Dalers

Corbion
-3,97%
ADYEN NV
-3,20%
EBUSCO...
-3,00%
SIGNIF...
-2,50%
PROSUS
-2,29%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!